Compare GPC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPC | NBIX |
|---|---|---|
| Founded | 1928 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 13.9B |
| IPO Year | 1994 | 1996 |
| Metric | GPC | NBIX |
|---|---|---|
| Price | $115.38 | $130.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 22 |
| Target Price | $145.67 | ★ $175.23 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 0.47 | ★ 4.67 |
| Revenue | ★ $24,300,141,000.00 | $161,626,000.00 |
| Revenue This Year | $4.89 | $22.57 |
| Revenue Next Year | $4.57 | $9.56 |
| P/E Ratio | $248.70 | ★ $28.05 |
| Revenue Growth | 3.46 | ★ 977.51 |
| 52 Week Low | $104.01 | $84.23 |
| 52 Week High | $151.57 | $160.18 |
| Indicator | GPC | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 29.34 | 44.90 |
| Support Level | N/A | $122.82 |
| Resistance Level | $129.07 | $137.37 |
| Average True Range (ATR) | 3.66 | 3.94 |
| MACD | -2.79 | 0.20 |
| Stochastic Oscillator | 2.71 | 41.64 |
Genuine Parts sells aftermarket automotive parts (60% of sales) and industrial products (40% of sales) in the United States and internationally. The automotive segment primarily acts as a distributor to its network of 9,800 global retail locations, of which about two-thirds are independently owned and operated. We estimate Genuine serves around 6,000 retail locations in the US operating under the Napa Auto Parts brand, with about 80% of end-market sales derived from professional customers. Its industrial segment, primarily operating under the Motion name in the United States, is a leading distributor of bearings, power transmission, and other industrial products to more than 200,000 maintenance, repair, and original equipment manufacturer customers.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.